1. Home
  2. SGMT vs LXFR Comparison

SGMT vs LXFR Comparison

Compare SGMT & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGMT
  • LXFR
  • Stock Information
  • Founded
  • SGMT 2006
  • LXFR 1898
  • Country
  • SGMT United States
  • LXFR United States
  • Employees
  • SGMT N/A
  • LXFR N/A
  • Industry
  • SGMT
  • LXFR Major Chemicals
  • Sector
  • SGMT
  • LXFR Industrials
  • Exchange
  • SGMT Nasdaq
  • LXFR Nasdaq
  • Market Cap
  • SGMT 269.2M
  • LXFR 314.6M
  • IPO Year
  • SGMT 2023
  • LXFR 2012
  • Fundamental
  • Price
  • SGMT $10.94
  • LXFR $11.86
  • Analyst Decision
  • SGMT Strong Buy
  • LXFR
  • Analyst Count
  • SGMT 6
  • LXFR 0
  • Target Price
  • SGMT $26.83
  • LXFR N/A
  • AVG Volume (30 Days)
  • SGMT 883.6K
  • LXFR 122.5K
  • Earning Date
  • SGMT 08-13-2025
  • LXFR 07-29-2025
  • Dividend Yield
  • SGMT N/A
  • LXFR 4.35%
  • EPS Growth
  • SGMT N/A
  • LXFR 49063.50
  • EPS
  • SGMT N/A
  • LXFR 0.79
  • Revenue
  • SGMT N/A
  • LXFR $399,500,000.00
  • Revenue This Year
  • SGMT N/A
  • LXFR $2.63
  • Revenue Next Year
  • SGMT N/A
  • LXFR $3.30
  • P/E Ratio
  • SGMT N/A
  • LXFR $15.20
  • Revenue Growth
  • SGMT N/A
  • LXFR 1.63
  • 52 Week Low
  • SGMT $1.73
  • LXFR $9.41
  • 52 Week High
  • SGMT $10.99
  • LXFR $15.64
  • Technical
  • Relative Strength Index (RSI)
  • SGMT 68.84
  • LXFR 48.67
  • Support Level
  • SGMT $8.79
  • LXFR $11.90
  • Resistance Level
  • SGMT $10.99
  • LXFR $12.18
  • Average True Range (ATR)
  • SGMT 0.74
  • LXFR 0.30
  • MACD
  • SGMT -0.05
  • LXFR -0.06
  • Stochastic Oscillator
  • SGMT 82.20
  • LXFR 26.39

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.

Share on Social Networks: